Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Pagano, Katiuscia ^a   Torella, Rubben ^b   Foglieni, Chiara ^c   Bugatti, Antonella ^d   Tomaselli, Simona ^a   Zetta, Lucia ^a   Presta, Marco ^d   Rusnati, Marco ^d   Taraboletti, Giulia ^c   Colombo, Giorgio ^b   Ragona, Laura ^a  

^a CNR   (Italy)

^b CNR   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; MEMBRANE PROTEIN; PROTEIN SM27; PROTEOHEPARAN SULFATE; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; FGFR1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MULTIPROTEIN COMPLEX; NAPHTHALENESULFONIC ACID DERIVATIVE;

ALLOSTERISM; AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; HYDROPHOBICITY; MOLECULAR DYNAMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SURFACE PLASMON RESONANCE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IN VITRO STUDY; MOLECULAR MIMICRY;

ALLOSTERIC REGULATION; ANGIOGENESIS INHIBITORS; FIBROBLAST GROWTH FACTOR 2; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MOLECULAR MIMICRY; MULTIPROTEIN COMPLEXES; NAPHTHALENESULFONATES; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN INTERACTION MAPPING; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SURFACE PLASMON RESONANCE; THROMBOSPONDIN 1;

EID: 84860993410     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036990     Document Type: Article

References (53)

1. Turner N, Grose R, (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10: 116-129.
2. Beenken A, Mohammadi M, (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253.
3. Wesche J, Haglund K, Haugsten EM, (2011) Fibroblast growth factors and their receptors in cancer. Biochemical Journal 437: 199-213.
4. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, et al. (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 87: 6624-6628.
5. Taraboletti G, Roberts D, Liotta LA, Giavazzi R, (1990) Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 111: 765-772.
6. Margosio B, Marchetti D, Vergani V, Giavazzi R, Rusnati M, et al. (2003) Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood 102: 4399-4406.
7. Taraboletti G, Belotti D, Borsotti P, Vergani V, Rusnati M, et al. (1997) The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ 8: 471-479.
8. Margosio B, Rusnati M, Bonezzi K, Cordes BL, Annis DS, et al. (2008) Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol 40: 700-709.
9. Colombo G, Margosio B, Ragona L, Neves M, Bonifacio S, et al. (2010) Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J Biol Chem 285: 8733-8742.
10. Fernandez-Tornero C, Lozano RM, Redondo-Horcajo M, Gomez AM, Lopez JC, et al. (2003) Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate. J Biol Chem 278: 21774-21781.
11. Taraboletti G, Rusnati M, Ragona L, Colombo G, (2010) Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget 1: 662-673.
12. Heath WF, Cantrell AS, Mayne NG, Jaskunas SR, (1991) Mutations in the heparin-binding domains of human basic fibroblast growth factor alter its biological activity. Biochemistry 30: 5608-5615.
13. Ibrahimi OA, Zhang F, Eliseenkova AV, Itoh N, Linhardt RJ, et al. (2004) Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet 13: 2313-2324.
14. Ibrahimi OA, Zhang F, Eliseenkova AV, Linhardt RJ, Mohammadi M, (2004) Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. Hum Mol Genet 13: 69-78.
15. Li LY, Safran M, Aviezer D, Bohlen P, Seddon AP, et al. (1994) Diminished heparin binding of a basic fibroblast growth factor mutant is associated with reduced receptor binding, mitogenesis, plasminogen activator induction, and in vitro angiogenesis. Biochemistry 33: 10999-11007.
16. Mohammadi M, Olsen SK, Ibrahimi OA, (2005) Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 16: 107-137.
17. Seno M, Sasada R, Kurokawa T, Igarashi K, (1990) Carboxyl-terminal structure of basic fibroblast growth factor significantly contributes to its affinity for heparin. Eur J Biochem 188: 239-245.
18. Moy FJ, Seddon AP, Bohlen P, Powers R, (1996) High-resolution solution structure of basic fibroblast growth factor determined by multidimensional heteronuclear magnetic resonance spectroscopy. Biochemistry 35: 13552-13561.
19. Ornitz DM, Herr AB, Nilsson M, Westman J, Svahn CM, et al. (1995) FGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharides. Science 268: 432-436.
20. Krishnamoorthy J, Yu VC, Mok YK, (2010) Auto-FACE: an NMR based binding site mapping program for fast chemical exchange protein-ligand systems. PLoS One 5: e8943.
21. de Vries SJ, van Dijk AD, Krzeminski M, van Dijk M, Thureau A, et al. (2007) HADDOCK versus HADDOCK: new features and performance of HADDOCK2.0 on the CAPRI targets. Proteins 69: 726-733.
22. Dominguez C, Boelens R, Bonvin AM, (2003) HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J Am Chem Soc 125: 1731-1737.
23. Mandel AM, Akke M, Palmer AG 3rd, (1995) Backbone dynamics of Escherichia coli ribonuclease HI: correlations with structure and function in an active enzyme. J Mol Biol 246: 144-163.
24. Niccolai N, Spadaccini R, Scarselli M, Bernini A, Crescenzi O, et al. (2001) Probing the surface of a sweet protein: NMR study of MNEI with a paramagnetic probe. Protein Sci 10: 1498-1507.
25. Otting G, (1997) NMR studies of water bound to biological molecules. Progress in Nuclear Magnetic Resonance Spectroscopy 31: 259-285.
26. Morra G, Neves MAC, Plescia CJ, Tsustsumi S, Neckers L, et al. (2010) Dynamics-Based Discovery of Allosteric Inhibitors: Selection of New Ligands for the C-terminal Domain of Hsp90. Journal of Chemical Theory and Computation 6: 2978-2989.
27. Morra G, Verkhivker G, Colombo G, (2009) Modeling signal propagation mechanisms and ligand-based conformational dynamics of the Hsp90 molecular chaperone full-length dimer. PLoS Comput Biol 5: e1000323.
28. Torella R, Moroni E, Caselle M, Morra G, Colombo G, (2010) Investigating dynamic and energetic determinants of protein nucleic acid recognition: analysis of the zinc finger zif268-DNA complexes. BMC Struct Biol 10: 42.
29. Pontiggia F, Zen A, Micheletti C, (2008) Small- and large-scale conformational changes of adenylate kinase: a molecular dynamics study of the subdomain motion and mechanics. Biophys J 95: 5901-5912.
30. Rusnati M, Urbinati C, Caputo A, Possati L, Lortat-Jacob H, et al. (2001) Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J Biol Chem 276: 22420-22425.
31. Moscatelli D, (1988) Metabolism of receptor-bound and matrix-bound basic fibroblast growth factor by bovine capillary endothelial cells. J Cell Biol 107: 753-759.
32. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, et al. (2000) Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 6: 743-750.
33. Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, et al. (2001) Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. J Biol Chem 276: 37900-37908.
34. Kar G, Keskin O, Gursoy A, Nussinov R, (2010) Allostery and population shift in drug discovery. Current Opinion in Pharmacology 10: 715-722.
35. Mauldin RV, Carroll MJ, Lee AL, (2009) Dynamic dysfunction in dihydrofolate reductase results from antifolate drug binding: modulation of dynamics within a structural state. Structure 17: 386-394.
36. Peng JW, (2009) Communication Breakdown: Protein Dynamics and Drug Design. Structure (London, England: 1993) 17: 319-320.
37. Fernandez IS, Cuevas P, Angulo J, Lopez-Navajas P, Canales-Mayordomo A, et al. (2010) Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors. J Biol Chem 285: 11714-11729.
38. Morra G, Potestio R, Micheletti C, Colombo G, (2012) Corresponding Functional Dynamics across the Hsp90 Chaperone Family: Insights from a Multiscale Analysis of MD Simulations. PLoS Comput Biol 8 (3): e1002433.
39. Bouguet-Bonnet S, Buck M, (2008) Compensatory and long-range changes in picosecond-nanosecond main-chain dynamics upon complex formation: 15N relaxation analysis of the free and bound states of the ubiquitin-like domain of human plexin-B1 and the small GTPase Rac1. J Mol Biol 377: 1474-1487.
40. Das R, Chowdhury S, Mazhab-Jafari MT, Sildas S, Selvaratnam R, et al. (2009) Dynamically driven ligand selectivity in cyclic nucleotide binding domains. J Biol Chem 284: 23682-23696.
41. Das R, Mazhab-Jafari MT, Chowdhury S, SilDas S, Selvaratnam R, et al. (2008) Entropy-driven cAMP-dependent allosteric control of inhibitory interactions in exchange proteins directly activated by cAMP. J Biol Chem 283: 19691-19703.
42. Ravindranathan S, Oberstrass FC, Allain FH, (2008) Increase in backbone mobility of the VTS1p-SAM domain on binding to SRE-RNA. J Mol Biol 396: 732-746.
43. Tzeng SR, Kalodimos CG, (2011) Protein dynamics and allostery: an NMR view. Curr Opin Struct Biol 21: 62-67.
44. Canales-Mayordomo A, Fayos R, Angulo J, Ojeda R, Martin-Pastor M, et al. (2006) Backbone dynamics of a biologically active human FGF-1 monomer, complexed to a hexasaccharide heparin-analogue, by 15N NMR relaxation methods. J Biomol NMR 35: 225-239.
45. Presta M, Oreste P, Zoppetti G, Belleri M, Tanghetti E, et al. (2005) Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists. Arterioscler Thromb Vasc Biol 25: 71-76.
46. Leali D, Bianchi R, Bugatti A, Nicoli S, Mitola S, et al. (2010) Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide. J Cell Mol Med 14: 2109-2121.
47. Case DA, Darden TA, Cheatham TEI, Simmerling CL, Wang J, et al. (2006) AMBER 9. University of California, San Francisco.
48. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML, (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79: 926-935.
49. Darden T, York D, Pedersen L, (1993) Particle Mesh Ewald-an N. Log(N) method for Ewald sums in large systems. J Chem Phys 98: 10089-10092.
50. Esko JD, (1991) Genetic analysis of proteoglycan structure, function and metabolism. Curr Opin Cell Biol 3: 805-816.
51. Liekens S, Leali D, Neyts J, Esnouf R, Rusnati M, et al. (1999) Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds. Mol Pharmacol 56: 204-213.
52. Taraboletti G, Belotti D, Dejana E, Mantovani A, Giavazzi R, (1993) Endothelial cell migration and invasiveness are induced by a soluble factor produced by murine endothelioma cells transformed by polyoma virus middle T oncogene. Cancer Res 53: 3812-3816.
53. Mulder FA, Schipper D, Bott R, Boelens R, (1999) Altered flexibility in the substrate-binding site of related native and engineered high-alkaline Bacillus subtilisins. J Mol Biol 292: 111-123.